SomaGenics develops and provides novel RNA-based gene inhibitors for functional genomics and therapeutics. The company specializes in tools and technologies for drug discovery. It researches inflammatory and autoimmune disorders, HIV and hepatitis C. SomaGenics primary platform technology is a gene-targeting approach called the RNA Lasso. RNA Lassos have potential applications in drug target discovery, therapeutics, research, and diagnostics. The RNA Lasso platform technology provides a significant advance in addressing diagnostics for research, agricultural, veterinary, food, and medical testing, as well as drug development and discovery. In addition to therapeutic development, SomaGenics has several technology applications available for licensing with partners. The company is based in Santa Cruz, Calif.